Please ensure Javascript is enabled for purposes of website accessibility

Ligand's Big Payout

By Brian Lawler – Updated Nov 15, 2016 at 12:47AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ligand decides to return some cash to shareholders.

When a pharmaceutical company gets bigger, and research and development expenses mask the cash flow that its marketed drugs are bringing in, it sometimes makes sense to separate out the cash flow-generating assets from the rest of the company to better realize their value. This was the reasoning behind activist hedge fund Third Point's breakup of Ligand Pharmaceuticals' (NASDAQ:LGND) operations in September, when it sold lead pain drug Avinza and its oncology product line.

In conjunction with the sale of these drugs, Ligand received $480 million from Japanese drugmaker Eisai and King Pharmaceuticals (NYSE:KG) and will receive a small royalty rate on sales of Avinza. Last year, sales of this drug were $137 million, up 21% over 2005. But prescription growth declined as sales and marketing operations transitioned to King.

Ligand currently has $415 million in cash and investments, but the dividend payout will reduce this to $160 million and change. This delectable return of cash to shareholders will amount to $2.50 a share, or nearly a 25% of Ligand's current stock price. Doling out a one-time dividend such as this is a good way to return cash to shareholders if there is no other good use for the money, but it's worth remembering that the stock price will fall by this amount once the cash is paid out.

Prior to the dividend, more than 40% of Ligand's market capitalization is supported by the cash and investments on its balance sheet. Breaking Ligand's operations apart and selling off some of its assets is part of Third Point's plan to unlock some of the hidden value in the company's shares. The plan has met with mixed success, with shares of Ligand trading in the middle of its 52-week range and about flat from when the asset sale was announced in September.

This is probably a small taste of what may be in store for other drug companies, like Nabi Biopharmaceuticals (NASDAQ:NABI) or PDL BioPharma (NASDAQ:PDLI), in Third Point has become involved, and which the activist group wants to break up. But whether this strategy succeeds in increasing long-run shareholder value remains to be seen.

PDL BioPharma is a Rule Breakers recommendation. Find out why when you take the newsletter for a free 30-day trial.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

PDL BioPharma, Inc. Stock Quote
PDL BioPharma, Inc.
PDLI

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.